Judge Lets Mousser Trial Evidence Aid Fancher Case
A federal judge allowed scientific testimony from one Camp Lejeune kidney cancer trial to be used in a second, related case.
Updated on Nov. 4, 2026 in Cancer
Federal Judge Terrence Boyle ruled that scientific evidence from Frank Mousser's trial can be used in David Fancher's trial, both involving kidney cancer after service at Camp Lejeune. Attorneys will not have to repeat much of the earlier scientific testimony, though they can still introduce evidence specific to Fancher's exposure, illness and damages.
Why it matters
The ruling could streamline litigation under the Camp Lejeune Justice Act for veterans and families pursuing claims tied to contaminated drinking water at the North Carolina base. It also shows how courts may handle overlapping scientific evidence across related health-based cases.
The order covers testimony and exhibits from the Mousser trial on contaminated water at Camp Lejeune and its potential health effects, with Fancher's trial set for November 9, 2026. A ruling in the first trial remains pending, and the extent to which the shared evidence will shape Fancher's outcome has not been determined.
The players
Terrence Boyle
Terrence Boyle is a federal judge in the U.S. District Court for the Eastern District of North Carolina who presides over Camp Lejeune Justice Act litigation.
Camp Lejeune
Camp Lejeune is a U.S. Marine Corps base in North Carolina whose drinking water was contaminated, leading to health claims by former service members and their families.
The details
Boyle's order lets attorneys in the Fancher case reuse much of the scientific testimony from the Mousser trial, which concerns kidney cancer linked to drinking water at Camp Lejeune. Attorneys can still present evidence specific to Fancher's exposure, illness and damages.
Timeline
November 9, 2026: Fancher's trial is scheduled to begin.
Health Landscape
The Camp Lejeune Justice Act created a legal path for service members to pursue claims over contaminated water at the base. This ruling shapes how that statute's cases proceed by allowing scientific findings from one trial to carry into another.
Veterans and families with Camp Lejeune kidney cancer claims may face shorter trials, since much of the scientific testimony from an earlier case can be reused. Individual exposure and damages evidence still has to be presented in each case.
The takeaway
Overlapping health claims can share scientific proof across cases, but each person's own exposure and medical history still matter in court.
What happens next
Fancher's trial is scheduled to begin November 9, 2026, when the shared Mousser evidence is expected to be presented.
Further reading
Explore more cancer coverage in North Carolina for related context.
Source note: This article includes information reported by Public Radio East.
